Arbutus Biopharma: 3 Abstracts Accepted at AASLD, AB-101 Poster of Distinction.

Arbutus Biopharma has had three abstracts featuring imdusiran data and one abstract featuring AB-101 data accepted for poster presentations at AASLD – The Liver Meeting 2025. Notably, the AB-101 abstract has been selected as a Poster of Distinction. These presentations highlight the company's progress toward a potential functional cure for chronic hepatitis B virus.

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced that four abstracts, featuring both imdusiran and AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025. Notably, one of these abstracts, featuring AB-101 data, has been selected as a Poster of Distinction. The presentations will take place from November 7 to 11, 2025, in Washington, DC.

The accepted abstracts include three featuring imdusiran data and one featuring AB-101 data. The imdusiran abstracts highlight the safety and tolerability of the therapy in chronic hepatitis B virus (cHBV) patients, as well as the potential for enhanced responsiveness to pegylated interferon alfa-2a when used in combination with imdusiran. The AB-101 abstract, recognized as a Poster of Distinction, focuses on the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of AB-101, an oral PD-L1 inhibitor, in cHBV patients.

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, with a pipeline that includes imdusiran (AB-729) and AB-101 for the treatment of cHBV infection. The company is also involved in legal disputes related to its patented LNP technology used in COVID-19 vaccines by Moderna and Pfizer/BioNTech.

The acceptance of these abstracts underscores Arbutus' progress in developing potential functional cures for HBV, a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from cHBV infection, with approximately 1.1 million deaths annually due to complications related to the infection.

The presentations will be available on the AASLD website beginning November 7, 2025, at 8:00 am ET, and will also be found on Arbutus' website in the Publications section.